Cancer Drug's Real-World performance under the microscope
NCT ID NCT07269249
Summary
This study is observing how well the drug dostarlimab works for patients with a specific type of advanced rectal cancer in real-world settings, outside of a controlled clinical trial. It will track 50 patients who have already received or will receive the drug as part of their standard care in Italy. The main goal is to measure how many patients' tumors shrink and to monitor the drug's safety in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica
NOT_YET_RECRUITINGNaples, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale
RECRUITINGNaples, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.